Agios Pharmaceuticals (AGIO)
AGIO
Rare Disease
BiotechSign Signal Grade
B
Signal Grade
78.8/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pdufa Date
100
Insider Buying
0
Clinical Activity
100
Short Interest
50
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
0
PubMed Publications
1
Catalyst Record
ClinicalTrials.gov aggregate. ClinicalTrials.gov
Short Interest
15.09%
Float Shorted
7.8
Days to Cover
MODERATE
Squeeze Risk
+5.1%
SI Change
INCREASING
Trend
7,449,166
Shares Short
Short interest: 15.09% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- mitapivat — sickle cell disease 2026-11-01
Recent News & SEC Filings
- 4 High-Risk Stocks Built for Big Returns
- Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales
- Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
- Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
- Agios Pharmaceuticals Q2 Earnings Call Highlights
- Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Agios Pharmaceuticals.
Full AGIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.